Scarica l'app Stockscreener
32.18
0.53%
-0.17
Dopo l'orario di chiusura:
32.18
Precedente Chiudi:
$32.35
Aprire:
$32.57
Volume 24 ore:
2.16M
Relative Volume:
1.91
Capitalizzazione di mercato:
$2.83B
Reddito:
$218.71M
Utile/perdita netta:
$-113.70M
Rapporto P/E:
-24.69
EPS:
-1.3034
Flusso di cassa netto:
$-73.47M
1 W Prestazione:
+3.94%
1M Prestazione:
-2.75%
6M Prestazione:
+13.39%
1 anno Prestazione:
+89.52%
Intervallo 1D:
$31.00
$32.84
Intervallo di 1 settimana:
$30.18
$38.10
Portata 52W:
$15.84
$39.28
Ideaya Biosciences Inc Stock (IDYA) Company Profile
Nome
Ideaya Biosciences Inc
Settore
Industria
Telefono
650-443-6209
Indirizzo
5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare IDYA vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IDYA
Ideaya Biosciences Inc
|
32.18 | 2.84B | 218.71M | -113.70M | -73.47M | -1.3034 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-07 | Ripresa | UBS | Buy |
| 2025-11-24 | Iniziato | Truist | Buy |
| 2025-09-18 | Iniziato | Guggenheim | Buy |
| 2025-09-04 | Iniziato | Barclays | Overweight |
| 2025-09-04 | Iniziato | Citizens JMP | Mkt Outperform |
| 2025-07-22 | Iniziato | TD Cowen | Buy |
| 2025-07-10 | Ripresa | Goldman | Neutral |
| 2025-06-26 | Iniziato | Wells Fargo | Overweight |
| 2024-11-18 | Iniziato | Stephens | Overweight |
| 2024-11-05 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-10-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-07-08 | Iniziato | Mizuho | Outperform |
| 2024-03-08 | Iniziato | BTIG Research | Buy |
| 2023-08-08 | Iniziato | SVB Securities | Outperform |
| 2023-05-24 | Iniziato | Goldman | Buy |
| 2023-04-24 | Aggiornamento | Stifel | Hold → Buy |
| 2023-03-23 | Iniziato | Berenberg | Buy |
| 2023-02-28 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-12-28 | Iniziato | CapitalOne | Overweight |
| 2022-10-27 | Iniziato | Citigroup | Buy |
| 2022-08-15 | Downgrade | Stifel | Buy → Hold |
| 2022-07-18 | Ripresa | Oppenheimer | Outperform |
| 2022-03-10 | Aggiornamento | Stifel | Hold → Buy |
| 2021-09-23 | Iniziato | Stifel | Hold |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-03-11 | Iniziato | Guggenheim | Buy |
| 2020-10-07 | Iniziato | Wedbush | Outperform |
| 2020-09-01 | Iniziato | Northland Capital | Outperform |
| 2020-07-13 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-06-17 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-06 | Iniziato | H.C. Wainwright | Buy |
| 2020-03-13 | Iniziato | ROTH Capital | Buy |
| 2019-10-17 | Iniziato | Oppenheimer | Outperform |
| 2019-09-10 | Iniziato | Robert W. Baird | Outperform |
| 2019-06-17 | Iniziato | Citigroup | Buy |
| 2019-06-17 | Iniziato | JP Morgan | Neutral |
| 2019-06-17 | Iniziato | Jefferies | Buy |
Mostra tutto
Ideaya Biosciences Inc Borsa (IDYA) Ultime notizie
Ideaya Biosciences Stock Not Fully Reflecting Phase 2/3 Data From Metastatic Uveal Melanoma Study, RBC Says - marketscreener.com
Trio of Bay Area cancer-fighting companies look to raise $1 billion on solid clinical trials - The Business Journals
Guggenheim raises Ideaya Biosciences stock price target on trial data By Investing.com - Investing.com Canada
RBC Capital raises Ideaya Biosciences stock price target on trial data - Investing.com Canada
Novo teams with OpenAI; Ideaya gets muted response to eye drug data - Yahoo Finance
IDEAYA Biosciences Unveils OptimUM-02 Data: Darovasertib/Crizotinib Doubles PFS in Uveal Melanoma - Yahoo Finance
IDEAYA Biosciences, Inc. (IDYA) Discusses Topline Results from OptimUM-02 Trial Evaluating Darovasertib and Crizotinib in HLA-A2-Negative Metastatic Uveal MelanomaSlideshow (NASDAQ:IDYA) 2026-04-13 - Seeking Alpha
IDEAYA Biosciences, Inc. (IDYA) Latest Stock News & Headlines - Yahoo Finance
Mizuho raises Ideaya Biosciences stock price target on trial data By Investing.com - Investing.com Canada
Ideaya Biosciences: Stock Buoyant On Good mUM DataBut Approval Not A Formality (IDYA) - Seeking Alpha
Truist raises Ideaya Biosciences stock price target on trial data By Investing.com - Investing.com Canada
IDEAYA’s uveal melanoma drug combo meets trial goals By Investing.com - Investing.com Australia
Goldman Sachs raises Ideaya Biosciences stock price target on trial data By Investing.com - Investing.com South Africa
Goldman Sachs raises Ideaya Biosciences stock price target on trial data - Investing.com Canada
IDEAYA Biosciences (IDYA) Stock Jumps 26% After Eye Cancer Trial Blows Past Standard Care - MEXC
IDEAYA Biosciences Announces Phase 2/3 Clinical Update for Darovasertib Combination in OptimUM-02 Trial - Minichart
IDEAYA and Servier's eye cancer drug meets trial goal, paving way for FDA application - Reuters
IDEAYA Biosciences (IDYA) Soars 26% on Breakthrough Eye Cancer Trial Data - MEXC
Shares of This Cancer Therapy Maker Are Up 14%. Here’s Why. - Barron's
IDEAYA Eye Cancer Trial Data Beats Standard Therapy, Stock SoarsIDEAYA Biosciences (NASDAQ:IDYA) - Benzinga
IDYA: Darovasertib plus crizotinib doubled PFS and improved ORR in HLA-A*02:01-negative mUM - TradingView — Track All Markets
IDEAYA Biosciences stock surges 27% on trial results - Investing.com
IDEAYA’s uveal melanoma drug combo meets trial goals - Investing.com
IDEAYA Biosciences' darovasertib+crizotinib cuts progression risk 58%, median PFS 6.9 vs 3.1 months - TradingView — Track All Markets
Darovasertib combo boosts PFS in IDEAYA (NASDAQ: IDYA) uveal melanoma trial - Stock Titan
IDEAYA Biosciences and Servier Announce Positive Topline Results from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA-A*02:01-Negative Metastatic Uveal Melanoma - PR Newswire
Why IDEAYA Biosciences Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket - Benzinga
Dip Buying: Can IDEAYA Biosciences Inc reach all time highs this year2026 Momentum & Low Risk Growth Stock Ideas - baoquankhu1.vn
Why Is Ideaya Biosciences (IDYA) Stock Surging Over 20% Overnight? - Stocktwits
IDEAYA Biosciences to Announce Topline Results from Phase 2/3 OptimUM-02 Trial in Metastatic Uveal Melanoma on Monday, April 13, 2026 - BioSpace
IDEAYA Biosciences to Announce Topline Results from Phase 2/3 Op - GuruFocus
IDYA Stock Pops As New Cancer Trials Ignite Trader Focus - timothysykes.com
Ideaya Biosciences to announce topline results from phase 2/3 Optimum-02 trial in metastatic uveal melanoma on Monday, April 13, 2026 - marketscreener.com
Ideaya Biosciences To Announce Topline Results From Phase 2/3 Optimum-02 Trial In Metastatic Uveal Melanoma On Monday, April 13, 2026 - TradingView — Track All Markets
IDEAYA to report uveal melanoma trial results Monday By Investing.com - Investing.com UK
IDEAYA to reveal April 13 trial data in metastatic uveal melanoma - Stock Titan
(IDYA) Volatility Zones as Tactical Triggers - Stock Traders Daily
IDEAYA’s April 13 PFS Results May Lead to Fast-Track Approval or Significant Revaluation - Bitget
Ideaya Biosciences announces clinical collaboration with AstraZeneca for lung cancer study - Investing.com
IDEAYA, AstraZeneca launch global IDE849-Imfinzi lung cancer trial - TipRanks
Ideaya Biosciences Incenters clinical collaboration agreement with AstraZeneca on April 8, 2026SEC filing - marketscreener.com
IDEAYA Biosciences IncAdvancing Global Pha - Moomoo
IDEAYA Biosciences (NASDAQ: IDYA) teams with AstraZeneca on IDE849-Imfinzi SCLC trial - Stock Titan
Ideaya Biosciences: Key Pivotal Data Imminent - Seeking Alpha
IDEAYA Biosciences Advances IDE574 Into Phase 1 As First Patient Enrolled For KAT6 And KAT7 Dual Inhibitor - BioPharma APAC
IDEAYA Biosciences, Inc. (IDYA) stock price, news, quote and history - Yahoo Finance UK
Analysts Offer Insights on Healthcare Companies: UnitedHealth (UNH), IDEAYA Biosciences (IDYA) and Bristol-Myers Squibb (BMY) - The Globe and Mail
Jefferies Initiates IDEAYA Biosciences(IDYA.US) With Buy Rating, Announces Target Price $52 - Moomoo
IDEAYA Biosciences Target of Unusually Large Options Trading (NASDAQ:IDYA) - MarketBeat
Ideaya enrolls first patient in phase 1 trial of KAT6/7 inhibitor - Investing.com Canada
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer - TradingView — Track All Markets
Ideaya Biosciences Inc Azioni (IDYA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.69%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):